GH Research (GHRS) Return on Capital Employed (2021 - 2025)
GH Research (GHRS) recorded quarterly Return on Capital Employed of 21.17% in Q4 2025, down 10.56% quarter-over-quarter from 19.15% in Q3 2025, and up 602.0% on a YoY basis from 3.02% in Q4 2024.
GH Research (GHRS) Return on Capital Employed (2021 - 2025) Analysis & Trends
GH Research's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 21.17% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 602.0% year-over-year to 21.17%; the TTM figure through Dec 2025 stood at 21.17% (up 602.0% YoY), while the FY2025 annual figure was 26.41%, down 105.0% from the prior year.
- Return on Capital Employed was 21.17% for Q4 2025 at GH Research, down from 19.15% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5.33% in Q4 2021 to a low of 27.2% in Q4 2024.
- Historically, Return on Capital Employed has averaged 16.65% across 5 years, with a median of 17.27% in 2025.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 869 bps in 2024, then surged 602 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 5.33% in 2021, then sank by 127 bps to 12.09% in 2022, then sank by 53 bps to 18.51% in 2023, then slumped by 47 bps to 27.2% in 2024, then climbed by 22 bps to 21.17% in 2025.
- The last three Return on Capital Employed figures came in at 21.17% (Q4 2025), 19.15% (Q3 2025), and 17.27% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -21.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.17% |
| Sep 30, 2025 | -19.15% |
| Jun 30, 2025 | -17.27% |
| Mar 31, 2025 | -21.07% |
| Dec 31, 2024 | -27.20% |
| Sep 30, 2024 | -25.08% |
| Jun 30, 2024 | -22.31% |
| Mar 31, 2024 | -19.72% |
| Dec 31, 2023 | -18.51% |
| Sep 30, 2023 | -17.04% |
| Jun 30, 2023 | -15.17% |
| Mar 31, 2023 | -13.45% |
| Dec 31, 2022 | -12.09% |
| Sep 30, 2022 | -10.78% |
| Jun 30, 2022 | -9.76% |
| Mar 31, 2022 | -7.94% |
| Dec 31, 2021 | -5.33% |